Related Experiment Video
Updated: Apr 29, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Update on screening, etiology, and treatment of dyslipidemia in children
1Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Insights
Updated pediatric guidelines for cardiovascular risk reduction emphasize early screening and management of dyslipidemia in children. Implementing these National Heart Lung and Blood Institute (NHLBI) guidelines is crucial for preventing future cardiovascular disease in youth.
Area of Science:
- Pediatric Cardiology
- Public Health
- Preventive Medicine
Background:
- Cardiovascular disease (CVD) is a major cause of illness and death.
- Early identification and management of CVD risk factors are essential for prevention.
- Updated 2011 pediatric guidelines from the National Heart Lung and Blood Institute (NHLBI) aim to reduce cardiovascular morbidity.
Purpose of the Study:
- To summarize recent NHLBI pediatric lipid guidelines.
- To discuss controversies surrounding these recommendations.
- To highlight common cholesterol disorders and dyslipidemia in pediatric diabetes.
Main Methods:
- Literature search of PubMed (2010-2013) for clinical studies.
- Review of NHLBI pediatric guidelines for cardiovascular risk reduction.
- Selection of relevant publications on pediatric dyslipidemia and cardiovascular disease.
Main Results:
- Guidelines recommend non-fasting non-HDL-C screening at ages 9-11.
- Aggressive lifestyle changes and statin therapy are advised for lipid management.
- Type 1 and type 2 diabetes are high-risk conditions with strict cholesterol targets.
Conclusions:
- Early identification and treatment of pediatric dyslipidemia are vital for reducing future CVD.
- Improved understanding and application of NHLBI guidelines can enhance cardiovascular outcomes in children.
Context:
Cardiovascular disease is a leading cause of morbidity and mortality. Early identification and treatment of risk factors that accelerate this condition are paramount to preventing disease. To this effect, the National Heart Lung and Blood Institute (NHLBI), endorsed by the American Academy of Pediatrics, issued updated pediatric guidelines for cardiovascular risk reduction in 2011. Integration of these guidelines into pediatric practice may lessen cardiovascular morbidity.
Evidence Acquisition:
In addition to reviewing the NHLBI guidelines, a detailed literature search was performed on PubMed for clinical studies published between 2010 and 2013. Key search terms included "pediatric dyslipidemia/hyperlipidemia," "cardiovascular disease," "atherosclerosis," "familial hypercholesterolemia," "hypertriglyceridemia," and "diabetes." Additional citations from these publications were also reviewed. Final publications were selected for their relevance to the topic.
Evidence Synthesis:
These guidelines contain several important recommendations relative to lipid management, including screening all children with nonfasting non-high-density lipoprotein-cholesterol at ages 9-11 years, incorporation of aggressive lifestyle changes to meet cholesterol targets, and initiation of statin therapy for those with low-density lipoprotein-cholesterol elevation. In addition, both type 1 and type 2 diabetes are now considered high-risk conditions and have stringent cholesterol targets. The primary aim is early identification of children with familial hypercholesterolemia; however, these recommendations have met with some controversy. The purpose of this update is to summarize these recent lipid guidelines, present the relevant controversies, highlight common cholesterol disorders, and discuss dyslipidemia specific to the pediatric diabetes population.
Conclusion:
Identification and treatment of youth with dyslipidemia is of paramount importance to the reduction of future cardiovascular disease. Increasing the comprehension and application of the newest NHLBI guidelines is critical to improving cardiovascular outcomes.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacokinetics in Pediatric Patients: Drug Metabolism

